Afatinib Dimaleate Intermediate CAS 314771-88-5 Maʻemaʻe >99.0% (HPLC) Hale Hana
ʻO Ruifu Nā Kūwaena Hoʻolako Kimia o Afatinib
Afatinib CAS 439081-18-2
Afatinib Dimaleate CAS 850140-73-7
(S)-(+)-3-Hydroxytetrahydrofuran CAS 86087-23-2
(Dimethylamino)acetaldehyde Diethyl Acetal CAS 3616-56-6
trans-4-Dimethylaminocrotonic Acid Hydrochloride CAS 848133-35-7
Diethylphosphonoacetic Acid CAS 3095-95-2
7-Fluoro-6-Nitroquinazolin-4(1H)-hoʻokahi CAS 162012-69-3
7-Chloro-6-Nitro-4-Hydroxyquinazoline CAS 53449-14-2
N-(3-Chloro-4-Fluorophenyl)-7-Fluoro-6-Nitroquinazolin-4-Amine CAS 162012-67-1
(S)-N4-(3-Chloro-4-Fluorophenyl)-7-((Tetrahydrofuran-3-yl)oxy)quinazoline-4,6-DiamineCAS 314771-76-1
(S)-N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl) oxy)quinazolin-4-AmineCAS 314771-88-5
Inoa Kimia | (S)-N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl) oxy)quinazolin-4-Amine |
Nā huaʻōlelo like | N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-[(3S)-oxolan-3-yl] oxyquinazolin-4-Amine;7-((S)-Tetrahydrofuran-3-yloxy)-4-(3-Chloro-4-Fluorophenyl) amino-6-Nitroquinazoline;Afatinib haumia |
Helu CAS | 314771-88-5 |
Helu CAT | RF-PI2027 |
Kūlana Kūʻai | Ma ka waihona, hoʻonui ʻia a hiki i nā tona |
ʻĀpana Molekala | C18H14ClFN4O4 |
Kaumaha Molecular | 404.78 |
ʻO ka mānoanoa | 1.534±0.060 g/cm3 |
Brand | Kemika Ruifu |
'ikamu | Nā kikoʻī |
Ka nana aku | Melemele a Melemele Māmā |
Maʻemaʻe / Kaʻina Hanana | >99.0% (HPLC) |
Nalo ma ka maloo | <0.50% |
Ka haumia o ke kanaka | <0.50% |
Huina paumaele | <1.00% |
Nā Metala Kaumaha | ≤20ppm |
Kūlana hoʻāʻo | Kūlana ʻoihana |
Hoʻohana | Waena o Afatinib Dimaleate (CAS: 850140-73-7) |
Pūʻolo: ʻOmole, ʻeke ʻeke Aluminum, 25kg / pahu pahu pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.
Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;E pale i ka malamalama a me ka wai
(S)-N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl)oxy)quinazolin-4-Amine (CAS: 314771-88-5) hoʻohana ʻia i ka hoʻomākaukau o Afatinib Dimaleate (CAS: 850140-73-7).ʻO Afatinib kahi lāʻau lapaʻau anti-cancer target hou, he hanauna hou o ka lāʻau i hoʻopaʻa ʻia i ka waha, ka lāʻau lapaʻau anti-cancer target mua loa o ka honua i hoʻopaʻa ʻole ʻia i ka ʻohana ErbB, a ʻoi aku ka maikaʻi a hoʻopaʻa ʻia. , hōʻemi a hoʻopaneʻe paha i ka hoʻonui ʻana o nā maʻi maʻi maʻi.Aia ʻo Afatinib i kahi papa o nā lāʻau i kapa ʻia ʻo tyrosine kinase inhibitors.Hana ia ma ka pale ʻana i ka hana o ʻelua mau protein pili pili, ka epidermal growth factor receptor (EGFR) a me ke kanaka epidermal growth factor receptor 2 (HER2).Hoʻohana ʻia no ka lāʻau lapaʻau mua o nā poʻe maʻi me ka maʻi maʻi ʻaʻa ʻole liʻiliʻi liʻiliʻi metastatic.ʻO Afatinib kahi lāʻau lapaʻau anti-cancer target hou, he hanauna hou o ka lāʻau i hoʻopaʻa ʻia i ka waha, ka lāʻau lapaʻau anti-cancer target mua loa o ka honua i hoʻopaʻa ʻole ʻia i ka ʻohana ErbB, a ʻoi aku ka maikaʻi a hoʻopaʻa ʻia. , hōʻemi a hoʻopaneʻe paha i ka hoʻonui ʻana o nā maʻi maʻi maʻi.